S. Shah

Safety and effectiveness of biphasic insulin aspart 30/70 (NovoMix® 30) when switching from human premix insulin in patients with type 2 diabetes: subgroup analysis from the 6-month IMPROVE™ observational study

P. Valensi, J. Gumprecht, R. Kawamori, 2009, International journal of clinical practice.

Efficacy and safety of ezetimibe co‐administered with simvastatin in thiazolidinedione‐treated type 2 diabetic patients

A. Lewin, L. Meneghini, I. Perevozskaya, 2005, Diabetes, obesity & metabolism.

Effects of an 11β‐hydroxysteroid dehydrogenase type 1 inhibitor, MK‐0916, in patients with type 2 diabetes mellitus and metabolic syndrome

E. Lai, K. Kaufman, E. Klein, 2011, Diabetes, obesity & metabolism.

Efficacy and safety of extended‐release niacin/laropiprant plus statin vs. doubling the dose of statin in patients with primary hypercholesterolaemia or mixed dyslipidaemia

J. Paolini, R. Češka, D. Maccubbin, 2010, International journal of clinical practice.

Initiating insulin therapy with, or switching existing insulin therapy to, biphasic insulin aspart 30/70 (NovoMix® 30) in routine care: safety and effectiveness in patients with type 2 diabetes in the IMPROVE™ observational study

P. Valensi, J. Gumprecht, R. Kawamori, 2009, International journal of clinical practice.

The IMPROVE™ study – a multinational, observational study in type 2 diabetes: baseline characteristics from eight national cohorts

P. Valensi, J. Gumprecht, R. Kawamori, 2008, International journal of clinical practice.